Profile of MIND MEDICINE MINDMED INC(NASDAQ:MNMD) stock

MIND MEDICINE MINDMED INC3.44

NASDAQ:MNMD (1/30/2023, 8:36:08 AM)0 (0%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Pharmaceuticals

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	08-11 2022-08-11/amc	Earnings (Next)	03-27 2023-03-27
Ins Owners	17.97%	Inst Owners	6.33%
Market Cap	96.88M	Shares	28.16M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	85.71
IPO	05-04 2015-05-04

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm is engaged in developing products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. The firm is developing a pipeline of drug candidates, targeting the serotonin, dopamine and acetylcholine systems. This specifically includes pharmaceutically optimized drug products derived from the psychedelic and empathogen drug classes, including lysergic acid diethylamide (LSD), R(-)-methylenedioxymethamphetamine (MDMA) and zolunicant, or 18-methoxycoronaridine (MC), a congener of ibogaine. The Company’s subsidiaries include Mind Medicine, Inc. (MindMed US), HealthMode, Inc., MindMed Pty Ltd., and MindMed GmbH.

Company Info

MIND MEDICINE MINDMED INC

1166 Alberni Steet, Suite 1604

Vancouver BRITISH COLUMBIA

P: 12122206633.0

Employees: 50

Website: https://mindmed.co/

MNMD News

4 days ago - FinancialNewsMediaPsychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry

EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END

4 days ago - FinancialNewsMedia.comPsychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry

/PRNewswire/ -- Even during the recent global supply chain problems, certain markets have continued to show growth. The psychedelic drugs markets is one of...

MIND MEDICINE MINDMED INC (MNMD) 3.44 0 (0%)

3.44 0 (0%)